$BMY Recent Headlines Alcoa shares rise on earnings,

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$BMY Recent Headlines

Alcoa shares rise on earnings, sales beat 6:55 p.m. Jan. 12, 2015 - MarketWatch
Bristol-Myers Squibb shares rise 5.7% 9:30 a.m. Jan. 12, 2015 - Sue Chang
Engage sick bags as stormy markets show no signs of calm 8:58 a.m. Jan. 12, 2015 - Shawn Langlois
Bristol-Myers Squibb jumps on Opdivo cancer drug test 8:17 a.m. Jan. 12, 2015 - Angela Chen
Bristol-Myers' stock climbs 6.3% premarket after positive trial results for Opdivo 8:16 a.m. Jan. 12, 2015 - Tomi Kilgore
FDA approves Bristol-Myers’s skin cancer treatment Opdivo 6:09 p.m. Dec. 22, 2014 - Ron Winslow
Steelcase shares slide as revenue comes in light 5:42 p.m. Dec. 22, 2014 - MarketWatch
FDA approves Bristol-Myers Squibb's Opdivo drug for treatment of skin cancer 5:29 p.m. Dec. 22, 2014 - Tom Bemis
Drug makers face another $65 billion patent cliff 12:41 p.m. Dec. 10, 2014 - Russ Britt
4 stocks to watch 1:44 p.m. Nov. 19, 2014 - The Trading Deck
77 stocks in the S&P 500 Index rise to new highs 10:50 a.m. Nov. 12, 2014 - Philip van Doorn
Charting a bullish post-election backdrop 11:04 a.m. Nov. 5, 2014 - Michael Ashbaugh
6 stocks to watch 2:35 p.m. Oct. 29, 2014 - The Trading Deck
Updates, advisories and surprises 12:31 p.m. Oct. 24, 2014 - MarketWatch
Amazon, Pandora sink in wake of results; KLA-Tencor surges 10:48 a.m. Oct. 24, 2014 - Sue Chang
Bristol-Myers profit slips, but tops expectations 7:45 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers sees 2014 total sales $15.2 bln-$15.8 bln vs. FactSet consensus $15.58 bln 7:35 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers lowers 2014 net EPS outlook to $1.15-$1.25 from $1.50-$1.60 7:34 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers affirms 2014 adj. EPS outlook of $1.70-$1.80 7:33 a.m. Oct. 24, 2014 - Tomi Kilgore
Bristol-Myers Q3 FactSet sales consensus $3.81 bln 7:33 a.m. Oct. 24, 2014 - Tomi Kilgore


Bristol-Myers' Opdivo - The New Cash Cow 9:08 a.m. Today - Seeking Alpha
Veteran Analyst’s Top Health-Care Picks for 2015 11:38 a.m. Jan. 15, 2015 - Barrons.com
Eli Lilly Has 'Turned The Corner,' Upgraded 10:02 a.m. Jan. 15, 2015 - Investors Business Daily
Celldex Therapeutics Still Building Its Immuno-Oncology Story 5:40 p.m. Jan. 14, 2015 - Seeking Alpha
Express Scripts is Biotech's Grinch 9:13 a.m. Jan. 14, 2015 - Seeking Alpha
Bristol-Myers Squibb (BMY) Stock Rises Today After Eli Lilly Collaboration 11:42 a.m. Jan. 13, 2015 - TheStreet.com
Bristol’s Lung Cancer Drug Aces Trial, Cheers Bulls 10:58 a.m. Jan. 13, 2015 - Barrons.com
Lilly to Collaborate on Cancer Drug Trials 8:52 a.m. Jan. 13, 2015 - The Wall Street Journal Interactive Edition
Bristol-Myers and Lilly team up in cancer 8:32 a.m. Jan. 13, 2015 - Seeking Alpha
'Mad Money' Lightning Round: Hold Onto WhiteWave, Bristol-Myers 6:00 a.m. Jan. 13, 2015 - TheStreet.com
'Fast Money' Recap: More Monday Mayhem as Oil Falls, Volatility Runs Wild 5:00 a.m. Jan. 13, 2015 - TheStreet.com
Medical Marijuana Goes to Market in Canada 3:10 a.m. Jan. 13, 2015 - InvestorPlace.com
Cramer's Lightning Round - Zimmer's Sweet Spot In The Marketplace (1/12/15) 1:32 a.m. Jan. 13, 2015 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses 8:32 p.m. Jan. 12, 2015 - TheStreet.com
Celgene, Bristol-Myers Cancer Drug News Lifts Stocks 5:48 p.m. Jan. 12, 2015 - Investors Business Daily
U.S. Stocks End Lower 4:41 p.m. Jan. 12, 2015 - The Wall Street Journal Interactive Edition
Gilead CEO’s Latest Sale Totals $14.3M 1:47 p.m. Jan. 12, 2015 - Barrons.com
Seattle Genetics and Bristol-Myers team up in blood cancer trials 1:44 p.m. Jan. 12, 2015 - Seeking Alpha
Bristol-Myers Hits 14-Year High On Cancer Drug Trial 1:25 p.m. Jan. 12, 2015 - Investors Business Daily
Why Bristol-Myers, Lululemon, and Foundation Medicine Are 3 of Today’s Best Stocks 10:39 a.m. Jan. 12, 2015 - InvestorPlace.com


Global Ankylosing Spondylitis Market 2015-2019 4:16 p.m. Jan. 14, 2015 - PR Newswire - PRF
Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors 8:02 a.m. Jan. 13, 2015 - BusinessWire - BZX
Bucking the Trend: New Research on RadioShack, Lululemon, Tekmira, Bristol-Myers and Alcoa 7:50 a.m. Jan. 13, 2015 - PR Newswire - PRF
Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin)and Opdivo® (Nivolumab) in Hematologic Malignancies 8:01 a.m. Jan. 12, 2015 - BusinessWire - BZX
CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early 9:06 p.m. Jan. 11, 2015 - BusinessWire - BZX
Global Psoriasis Therapeutics Market 2015-2019 2:12 p.m. Jan. 7, 2015 - PR Newswire - PRF
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference 9:30 a.m. Jan. 6, 2015 - BusinessWire - BZX
Stocks Cheering This Festive Season: Featured Research on Bristol-Myers, Rite Aid, Boeing, TASER and BioCryst 9:10 a.m. Dec. 23, 2014 - PR Newswire - PRF
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration 5:21 p.m. Dec. 22, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab) 3:11 p.m. Dec. 22, 2014 - BusinessWire - BZX
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27 10:01 a.m. Dec. 17, 2014 - BusinessWire - BZX
Pharma Equities Technical Analysis -- GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceutical Industries, Endo Intl., and Allergan 9:05 a.m. Dec. 17, 2014 - PR Newswire - PRF
Fitch Revises Bristol-Myers Squibb's Outlook to Stable; Affirms IDR at 'A-' 3:00 p.m. Dec. 11, 2014 - BusinessWire - BZX
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors 6:00 a.m. Dec. 10, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Announces Dividend 4:30 p.m. Dec. 9, 2014 - BusinessWire - BZX
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 1:00 p.m. Dec. 6, 2014 - BusinessWire - BZX
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Millionin New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries 9:01 a.m. Dec. 1, 2014 - BusinessWire - BZX
Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C 11:34 a.m. Nov. 26, 2014 - BusinessWire - BZX

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hitachi Energy: Spearheading Grid Management Transformation

Updated Category News Views 69

Blasting through the tangled mess of modern power distribution, Hitachi Energy's got something to crow about. They've just been hailed as a Leader in the 2026 IDC MarketScape for their advanced distribution management systems (ADMS). It's a title that's worth the ink, not just for the bragging rights but for what their platform can do for today's utilities—facing down...

Continue Reading
Rizzi Steps Down; Mogler Takes Helm at ALTOUR

Updated Category News Views 54

Changes in Leadership: The ALTOUR Shakeup You know, in the travel world, shifts in leadership can be quite the rollercoaster ride. We're talking about some pretty big shoes to fill over at ALTOUR, with Gabe Rizzi stepping back after a decade of driving the company's dynamic evolution. He’s not entirely out of the picture, though. Rizzi’s going to hang around as a...

Continue Reading
ARDX Shareholders Face Class Action Deadline Nov. 16

Updated Category News Views 17

Spotlight on Ardelyx: The Legal Smoke Signal Ah, lawsuits. They're like bad weather for companies—sometimes, you know they're coming, and they still hit you hard. Ardelyx's investors who've been in the game from January 13, 2025, to August 6, 2026, are now dealing with just such a storm. What's the Lawsuit Racket? Faruqi & Faruqi, LLP, a securities law firm that seems...

Continue Reading
Aspen Dental's Record-Breaking Day Serves Veterans

Updated Category News Views 27

Setting a New Benchmark in Charity Care Well, hold onto your hats, because Aspen Dental just smashed it out of the park with their latest Day of Service effort, a barnburner of an event held on November 7, 2026. These folks went all out, delivering free dental care to more than 6,400 veterans in a single day—yeah, you read that right. The whole shebang was valued at a...

Continue Reading
NatGold Aims Nasdaq Listing: Digital Gold Future?

Updated Category News Views 1975

NatGold's Bold Move Towards Nasdaq NatGold Digital's aiming to roll the dice on a Nasdaq Capital Market listing isn't just an administrative shuffle. They're talking about stepping into the big leagues with their quirky combo of digital gold mining and asset tokenization. Now, this might sound like just another press release, but trust me, whenever a company sets its...

Continue Reading
Data Center Laminated Busbars: $0.66B Market by 2031

Updated Category News Views 56

Shifts in Power: The Rise of Laminated Busbars Seeing the laminated busbar market trajectory kind of reminds me of watching a slow-boiling pot suddenly erupt. Projected to sprout from $0.31 billion in 2026 to $0.66 billion by 2031, it's like betting on a dark horse in the tech race that's finally hitting its stride. What's Driving Demand in Data Centers? With AI and cloud...

Continue Reading
FIS Under Investigation: Legal Woes Hit Shareholders

Updated Category News Views 27

When Forecasts Falter: A Reality Check for FIS Investors You ever get the feeling a company is just a bit too optimistic? Well, Fidelity National Information Services, Inc. (NYSE: FIS) might've been playing that game up until its recent fiscal hiccup. The mess started on November 4, 2026, when FIS decided to slash its fiscal 2026 adjusted EPS outlook. From a Wall Street...

Continue Reading
CAE Boosts Fiscal 2027 Outlook; Transformation On Track

Updated Category News Views 21

Revenue's down by a hair, but it's not as bleak as it seems. CAE Inc. (NASDAQ:CAE) just put its cards on the table for Q2 of fiscal 2027, and there's a mixed bag for us investors to chew over. Revenue dipped 2.6% year-over-year to $1,204.7 million. But hey, their adjusted EPS has climbed up to $0.33, a step up from $0.28 last year, which is a good sign of something right...

Continue Reading
SolidRun Unveils Unified Platform for Industrial AI

Updated Category News Views 71

SolidRun Steers the Future of Industrial AI SolidRun's newest venture appears as bold as a bull in a china shop, shaking up the industrial AI market with a comprehensive product line integrating NXP's i.MX 95 System-on-Modules and NVIDIA's Holoscan. What's the big deal? They're connecting the dots across the entire tech stack under one roof, flattening some hills that...

Continue Reading
COP31 Highlights: Energy Transition's Role in Competition

Updated Category News Views 57

Energy Transition: The New Competitive Edge Forget everything you thought you knew about energy as just a line item in an industry ledger. At the heart of the ongoing COP31 gathering in Antalya, Türkiye, is the revelation that energy has morphed into something greater—it's become the battleground for global competitive advantage. Ali Y. Koç didn't mince words when he...

Continue Reading
Management Transformation"> Continue Reading